Genprex new license agreement expands oncology franchise

Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including:

• Pembrolizumab (Merck’s largest selling drug Keytruda®)
• Nivolumab (Bristol-Myers Squibb’s Opdivo®)
• Ipilimumab (Bristol-Myers Squibb’s Yervoy®)

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a Patent and Technology License Agreement (“License Agreement”) with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in which MD Anderson granted to Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related technology (“Licensed IP”) for the treatment of cancer using Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or “GEN-001,” in combination with immunotherapies. This is a distinct therapeutic approach from that of combining Oncoprex with targeted therapies such as osimertinib (marketed as Tagrisso® by AstraZeneca).
Genprex was recently awarded U.S. FDA Fast Track designation for use of Oncoprex combined with Tagrisso for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations whose tumors progressed after treatment with Tagrisso alone. The Company is now preparing to file an Investigational New Drug application to initiate a clinical trial of Oncoprex in combination with pembrolizumab (marketed as Keytruda® by Merck) in NSCLC.
https://www.businesswire.com/news/home/20200505005133/en/Genprex-Enters-Exclusive-Worldwide-Patent-Technology-License